相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。HAWK and HARRIER: Phase 3, Multicenter, Randomized, Double-Masked Trials of Brolucizumab for Neovascular Age-Related Macular Degeneration
Pravin U. Dugel et al.
OPHTHALMOLOGY (2020)
Spectral-Domain OCT-Based Prevalence and Progression of Macular Atrophy in the HARBOR Study for Neovascular Age-Related Macular Degeneration
Shamika Gune et al.
OPHTHALMOLOGY (2020)
Efficacy and Safety of Intravitreal Aflibercept Treat-and-Extend Regimens in Exudative Age-Related Macular Degeneration: 52-and 96-Week Findings from ALTAIR A Randomized Controlled Trial
Masahito Ohji et al.
ADVANCES IN THERAPY (2020)
Efficacy of a Treat-and-Extend Regimen With Ranibizumab in Patients With Neovascular Age-Related Macular Disease A Randomized Clinical Trial
Peter J. Kertes et al.
JAMA OPHTHALMOLOGY (2020)
SIERRA-AMD: A Retrospective, Real-World Evidence Study of Patients with Neovascular Age-Related Macular Degeneration in the United States
Arshad M. Khanani et al.
OPHTHALMOLOGY RETINA (2020)
The Port Delivery System with Ranibizumab for Neovascular Age-Related Macular Degeneration Results from the Randomized Phase 2 Ladder Clinical Trial
Peter A. Campochiaro et al.
OPHTHALMOLOGY (2019)
Intralesional Macular Atrophy in Anti-Vascular Endothelial Growth Factor Therapy for Age-Related Macular Degeneration in the IVAN Trial
Clare Bailey et al.
OPHTHALMOLOGY (2019)
Real-World Vision in Age-Related Macular Degeneration Patients Treated with Single Anti-VEGF Drug Type for 1 Year in the IRIS Registry
Prethy Rao et al.
OPHTHALMOLOGY (2018)
Consensus Definition for Atrophy Associated with Age-Related Macular Degeneration on OCT Classification of Atrophy Report 3
Srinivas R. Sadda et al.
OPHTHALMOLOGY (2018)
Real-world Outcomes of Anti-Vascular Endothelial Growth Factor Therapy in Neovascular Age-Related Macular Degeneration in the United States
Thomas A. Ciulla et al.
OPHTHALMOLOGY RETINA (2018)
Real-world visual outcomes in patients with neovascular age-related macular degeneration receiving aflibercept at fixed intervals as per UK licence
Mehmet Ozturk et al.
CLINICAL AND EXPERIMENTAL OPHTHALMOLOGY (2018)
Neovascular age-related macular degeneration management in the third year: final results from the TREX-AMD randomised trial
Charles C. Wykoff et al.
BRITISH JOURNAL OF OPHTHALMOLOGY (2018)
Treat-and-Extend Therapy Using Aflibercept for Neovascular Age-related Macular Degeneration: A Prospective Clinical Trial
Francis Char Decroos et al.
AMERICAN JOURNAL OF OPHTHALMOLOGY (2017)
Caregiver perceptions about the impact of caring for patients with wet age-related macular degeneration
M. Vukicevic et al.
EYE (2016)
Five-Year Outcomes with Anti-Vascular Endothelial Growth Factor Treatment of Neovascular Age-Related Macular Degeneration The Comparison of Age-Related Macular Degeneration Treatments Trials
Maureen G. Maguire et al.
OPHTHALMOLOGY (2016)
Disease Burden in the Treatment of Age-Related Macular Degeneration: Findings From a Time-and-Motion Study
Jonathan L. Prenner et al.
AMERICAN JOURNAL OF OPHTHALMOLOGY (2015)
Long-Term Outcomes in Eyes Receiving Fixed-Interval Dosing of Anti-Vascular Endothelial Growth Factor Agents for Wet Age-Related Macular Degeneration
Marc C. Peden et al.
OPHTHALMOLOGY (2015)
Caregiver Burden in Patients Receiving Ranibizumab Therapy for Neovascular Age Related Macular Degeneration
Rishma Gohil et al.
PLOS ONE (2015)
Multi-country real-life experience of anti-vascular endothelial growth factor therapy for wet age-related macular degeneration
Frank G. Holz et al.
BRITISH JOURNAL OF OPHTHALMOLOGY (2015)
Current barriers to treatment for wet age-related macular degeneration (wAMD): findings from the wAMD patient and caregiver survey
Monica Varano et al.
CLINICAL OPHTHALMOLOGY (2015)
The Neovascular Age-Related Macular Degeneration Database: Multicenter Study of 92 976 Ranibizumab Injections
Adnan Tufail et al.
OPHTHALMOLOGY (2014)
Treatment patterns, visual acuity and quality-of-life outcomes of the WAVE study - A noninterventional study of ranibizumab treatment for neovascular age-related macular degeneration in Germany
Robert P. Finger et al.
ACTA OPHTHALMOLOGICA (2013)
Twelve-Month Efficacy and Safety of 0.5 mg or 2.0 mg Ranibizumab in Patients with Subfoveal Neovascular Age-related Macular Degeneration
Brandon G. Busbee et al.
OPHTHALMOLOGY (2013)
CHANGES IN VISUAL ACUITY IN PATIENTS WITH WET AGE-RELATED MACULAR DEGENERATION TREATED WITH INTRAVITREAL RANIBIZUMAB IN DAILY CLINICAL PRACTICE The LUMIERE Study
Salomon Y. Cohen et al.
RETINA-THE JOURNAL OF RETINAL AND VITREOUS DISEASES (2013)
HORIZON: An Open-Label Extension Trial of Ranibizumab for Choroidal Neovascularization Secondary to Age-Related Macular Degeneration
Michael A. Singer et al.
OPHTHALMOLOGY (2012)
Intravitreal Aflibercept (VEGF Trap-Eye) in Wet Age-related Macular Degeneration
Jeffrey S. Heier et al.
OPHTHALMOLOGY (2012)
Ranibizumab and Bevacizumab for Neovascular Age-Related Macular Degeneration The CATT Research Group
Daniel F. Martin et al.
NEW ENGLAND JOURNAL OF MEDICINE (2011)
Ranibizumab versus Verteporfin Photodynamic Therapy for Neovascular Age-Related Macular Degeneration: Two-Year Results of the ANCHOR Study
David M. Brown et al.
OPHTHALMOLOGY (2009)
Ranibizumab for neovascular age-related macular degeneration
Philip J. Rosenfeld et al.
NEW ENGLAND JOURNAL OF MEDICINE (2006)
Ranibizumab versus verteporfin for neovascular age-related macular degeneration
David M. Brown et al.
NEW ENGLAND JOURNAL OF MEDICINE (2006)
分享论文
